{"product_id":"crystagen-20mg-vial","title":"Crystagen 20mg vial","description":"\u003cp data-start=\"103\" data-end=\"389\"\u003e\u003cstrong\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e                                               \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003eFOR HUMAN CONSUMPTION\u003c\/span\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-start=\"103\" data-end=\"389\"\u003e\u003cstrong data-start=\"103\" data-end=\"116\"\u003eCrystagen\u003c\/strong\u003e is marketed within the Khavinson-style “peptide bioregulator\/cytogen” category as an \u003cstrong data-start=\"202\" data-end=\"228\"\u003eimmune-system–directed\u003c\/strong\u003e short-peptide preparation, often framed as \u003cstrong data-start=\"272\" data-end=\"297\"\u003ethymus\/immune support\u003c\/strong\u003e. A key practical issue is that \u003cstrong data-start=\"329\" data-end=\"388\"\u003e“Crystagen” is not consistently defined across catalogs\u003c\/strong\u003e:\u003c\/p\u003e\n\u003cul data-start=\"391\" data-end=\"1335\"\u003e\n\u003cli data-start=\"391\" data-end=\"685\"\u003e\n\u003cp data-start=\"393\" data-end=\"685\"\u003eSome product-line materials describe Crystagen as a \u003cstrong data-start=\"445\" data-end=\"464\"\u003epeptide complex\u003c\/strong\u003e associated with the \u003cstrong data-start=\"485\" data-end=\"509\"\u003ethymus\/immune system\u003c\/strong\u003e(commonly referenced as \u003cstrong data-start=\"534\" data-end=\"542\"\u003eAC-6\u003c\/strong\u003e) and position it for immune normalization after infections, radiation\/chemotherapy, stress, and aging. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"686\" data-end=\"1039\"\u003e\n\u003cp data-start=\"688\" data-end=\"1039\"\u003eOther brochures contain \u003cstrong data-start=\"712\" data-end=\"740\"\u003einternal inconsistencies\u003c\/strong\u003e (e.g., one section lists Crystagen under immune system but prints “AC-7 (bronchopulmonary tree)” nearby, while elsewhere stating \u003cstrong data-start=\"870\" data-end=\"913\"\u003eAC-6 corresponds to immune-system cells\u003c\/strong\u003e). This strongly suggests either layout error or cross-labeling within marketing PDFs. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1040\" data-end=\"1335\"\u003e\n\u003cp data-start=\"1042\" data-end=\"1335\"\u003eMultiple retailers describe Crystagen as a “peptide complex” containing the amino acids \u003cstrong data-start=\"1130\" data-end=\"1168\"\u003eproline, glutamine, and asparagine\u003c\/strong\u003e (a simplified composition statement that may refer to a particular formulation rather than a single defined peptide sequence). \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"1337\" data-end=\"1538\"\u003e\u003cstrong data-start=\"1337\" data-end=\"1365\"\u003eBottom line on identity:\u003c\/strong\u003e In professional scientific writing, treat “Crystagen” as a \u003cstrong data-start=\"1425\" data-end=\"1448\"\u003ebranded preparation\u003c\/strong\u003e unless you have \u003cstrong data-start=\"1465\" data-end=\"1495\"\u003ebatch-specific COA\/MS\/HPLC\u003c\/strong\u003e confirming an exact molecular composition.\u003c\/p\u003e\n\u003chr data-start=\"1540\" data-end=\"1543\"\u003e\n\u003ch3 data-start=\"1545\" data-end=\"1630\"\u003e2) Mechanistic rationale: what “immune bioregulator peptides” are \u003cem data-start=\"1615\" data-end=\"1624\"\u003eclaimed\u003c\/em\u003e to do\u003c\/h3\u003e\n\u003cp data-start=\"1631\" data-end=\"2091\"\u003eThe bioregulator framework proposes that \u003cstrong data-start=\"1672\" data-end=\"1705\"\u003eshort peptides (often 2–4 aa)\u003c\/strong\u003e can modulate tissue homeostasis by influencing \u003cstrong data-start=\"1753\" data-end=\"1829\"\u003ecell fate, proliferation\/apoptosis balance, and gene-expression programs\u003c\/strong\u003e in a tissue-biased way. For Crystagen, the strongest mechanistic anchors in the peer-indexed literature are \u003cstrong data-start=\"1938\" data-end=\"1975\"\u003eimmune-cell subpopulation effects\u003c\/strong\u003e and \u003cstrong data-start=\"1980\" data-end=\"2022\"\u003eapoptosis\/proliferation marker changes\u003c\/strong\u003e in aging immune tissue models. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-start=\"2093\" data-end=\"2096\"\u003e\n\u003ch2 data-start=\"2098\" data-end=\"2169\"\u003e3) Molecular mechanism of action (best-supported, evidence-weighted)\u003c\/h2\u003e\n\u003ch3 data-start=\"2171\" data-end=\"2242\"\u003e3.1 Primary biological “targets” (functional, not receptor-defined)\u003c\/h3\u003e\n\u003cp data-start=\"2243\" data-end=\"2471\"\u003eCrystagen is not characterized like a classical receptor agonist. The best-described “targets” are \u003cstrong data-start=\"2342\" data-end=\"2389\"\u003eimmune cell populations and renewal markers\u003c\/strong\u003e, assessed via immunocytochemical marker expression in organotypic spleen culture.\u003c\/p\u003e\n\u003cp data-start=\"2473\" data-end=\"2543\"\u003eIn \u003cstrong data-start=\"2476\" data-end=\"2515\"\u003eaged rat spleen organotypic culture\u003c\/strong\u003e, Crystagen was reported to:\u003c\/p\u003e\n\u003cul data-start=\"2544\" data-end=\"2948\"\u003e\n\u003cli data-start=\"2544\" data-end=\"2677\"\u003e\n\u003cp data-start=\"2546\" data-end=\"2677\"\u003e\u003cstrong data-start=\"2546\" data-end=\"2579\"\u003eIncrease CD20 (B-cell marker)\u003c\/strong\u003e area vs control (≈ \u003cstrong data-start=\"2599\" data-end=\"2611\"\u003e1.5-fold\u003c\/strong\u003e in the reported dataset). \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2678\" data-end=\"2948\"\u003e\n\u003cp data-start=\"2680\" data-end=\"2948\"\u003eShow \u003cstrong data-start=\"2685\" data-end=\"2711\"\u003eno meaningful increase\u003c\/strong\u003e in markers of “cellular renewal” such as \u003cstrong data-start=\"2753\" data-end=\"2762\"\u003eKi-67\u003c\/strong\u003e (proliferation) compared with other peptides in the same study—i.e., it appeared \u003cstrong data-start=\"2844\" data-end=\"2861\"\u003eB-cell–skewed\u003c\/strong\u003e rather than broadly pro-renewal in that model. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"2950\" data-end=\"2986\"\u003e3.2 Systems-level interpretation\u003c\/h3\u003e\n\u003cp data-start=\"2987\" data-end=\"3329\"\u003e\u003cstrong data-start=\"2987\" data-end=\"3062\"\u003eMost defensible mechanistic interpretation from available primary data:\u003c\/strong\u003e\u003cbr data-start=\"3062\" data-end=\"3065\"\u003eCrystagen behaves as an \u003cstrong data-start=\"3089\" data-end=\"3135\"\u003eimmunomodulatory short-peptide preparation\u003c\/strong\u003e with \u003cstrong data-start=\"3141\" data-end=\"3178\"\u003eB-cell–directed signaling effects\u003c\/strong\u003e in an aging immune-tissue model, without a strong proliferative\/renewal signature in that same spleen setting. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-start=\"3331\" data-end=\"3334\"\u003e\n\u003ch2 data-start=\"3336\" data-end=\"3414\"\u003e4) Pharmacokinetics and exposure constraints (what can be said responsibly)\u003c\/h2\u003e\n\u003cp data-start=\"3415\" data-end=\"3564\"\u003eCrystagen does \u003cstrong data-start=\"3430\" data-end=\"3437\"\u003enot\u003c\/strong\u003e have an FDA\/EMA drug label, and there is \u003cstrong data-start=\"3479\" data-end=\"3528\"\u003eno universally authoritative human PK profile\u003c\/strong\u003e. However, general principles apply:\u003c\/p\u003e\n\u003cul data-start=\"3566\" data-end=\"4091\"\u003e\n\u003cli data-start=\"3566\" data-end=\"3754\"\u003e\n\u003cp data-start=\"3568\" data-end=\"3754\"\u003eIf the active material includes \u003cstrong data-start=\"3600\" data-end=\"3623\"\u003every short peptides\u003c\/strong\u003e, they are often \u003cstrong data-start=\"3640\" data-end=\"3660\"\u003erapidly degraded\u003c\/strong\u003e by peptidases unless protected by formulation, delivery route, or specific sequence features.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3755\" data-end=\"4091\"\u003e\n\u003cp data-start=\"3757\" data-end=\"4091\"\u003eReal-world products are frequently \u003cstrong data-start=\"3792\" data-end=\"3811\"\u003eoral\/sublingual\u003c\/strong\u003e preparations; absorption and systemic exposure in humans are therefore \u003cstrong data-start=\"3883\" data-end=\"3925\"\u003euncertain without formal PK\/PD studies\u003c\/strong\u003e. (Some vendor dosing pages describe sublingual drops and an AC-6 amount per daily dose, but that is not a substitute for PK.) \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"4093\" data-end=\"4096\"\u003e\n\u003ch2 data-start=\"4098\" data-end=\"4117\"\u003e5) Evidence base\u003c\/h2\u003e\n\u003ch3 data-start=\"4119\" data-end=\"4165\"\u003e5.1 Preclinical \/ translational (stronger)\u003c\/h3\u003e\n\u003cp data-start=\"4166\" data-end=\"4225\"\u003e\u003cstrong data-start=\"4166\" data-end=\"4225\"\u003eAging immune tissue model (organotypic spleen culture):\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-start=\"4226\" data-end=\"4476\"\u003e\n\u003cli data-start=\"4226\" data-end=\"4476\"\u003e\n\u003cp data-start=\"4228\" data-end=\"4476\"\u003eDifferential effects of short peptides (vilon, thymogen, crystagen, R-1) on immune markers in old rats, with Crystagen showing \u003cstrong data-start=\"4355\" data-end=\"4376\"\u003eB-cell activation\u003c\/strong\u003e (CD20) but limited effect on renewal markers (e.g., Ki-67). \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"4478\" data-end=\"4553\"\u003e5.2 Human\/field evidence (weaker; often mixed with programmatic claims)\u003c\/h3\u003e\n\u003cp data-start=\"4554\" data-end=\"5132\"\u003eA 2021 review discussing thymus-derived peptide preparations notes that \u003cstrong data-start=\"4626\" data-end=\"4690\"\u003eoral Crystagen used in combination with other short peptides\u003c\/strong\u003e was associated with \u003cstrong data-start=\"4711\" data-end=\"4742\"\u003eincreased stress resistance\u003c\/strong\u003e and \u003cstrong data-start=\"4747\" data-end=\"4776\"\u003enormalization of immunity\u003c\/strong\u003e in athletes, including reported changes in \u003cstrong data-start=\"4820\" data-end=\"4852\"\u003eHSPA1A (HSP gene) expression\u003c\/strong\u003e and \u003cstrong data-start=\"4857\" data-end=\"4865\"\u003eIL-6\u003c\/strong\u003e expression, along with fewer respiratory viral infections in that context. This is suggestive but should be treated as \u003cstrong data-start=\"4985\" data-end=\"5015\"\u003eprogrammatic\/observational\u003c\/strong\u003e unless the underlying study design and endpoints are independently reviewed. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-start=\"5134\" data-end=\"5399\"\u003eBrochure-style product documents claim “clinical studies” supporting use after infections, radiation\/chemotherapy, stress, and in older adults; these are \u003cstrong data-start=\"5288\" data-end=\"5333\"\u003enot presented as transparent RCT datasets\u003c\/strong\u003e in the brochure itself. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-start=\"5401\" data-end=\"5404\"\u003e\n\u003ch2 data-start=\"5406\" data-end=\"5465\"\u003e6) Safety and tolerability (risk-based, not label-based)\u003c\/h2\u003e\n\u003cp data-start=\"5466\" data-end=\"5625\"\u003eBecause Crystagen is generally distributed as a \u003cstrong data-start=\"5514\" data-end=\"5541\"\u003esupplement\/bioregulator\u003c\/strong\u003e rather than an approved medicine, safety must be framed by \u003cstrong data-start=\"5601\" data-end=\"5624\"\u003eknown uncertainties\u003c\/strong\u003e:\u003c\/p\u003e\n\u003cul data-start=\"5627\" data-end=\"6332\"\u003e\n\u003cli data-start=\"5627\" data-end=\"5920\"\u003e\n\u003cp data-start=\"5629\" data-end=\"5920\"\u003e\u003cstrong data-start=\"5629\" data-end=\"5657\"\u003eComposition variability:\u003c\/strong\u003e “Crystagen” may refer to different peptide complexes (AC-6 vs ambiguous brochure labeling), and some sources reduce composition to a few amino acids—this variability increases uncertainty about reproducible pharmacology. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5921\" data-end=\"6102\"\u003e\n\u003cp data-start=\"5923\" data-end=\"6102\"\u003e\u003cstrong data-start=\"5923\" data-end=\"5954\"\u003eQuality\/contamination risk:\u003c\/strong\u003e For any non-pharmaceutical peptide product line, purity and consistency depend on manufacturing controls and documentation (COA, identity testing).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6103\" data-end=\"6332\"\u003e\n\u003cp data-start=\"6105\" data-end=\"6332\"\u003e\u003cstrong data-start=\"6105\" data-end=\"6129\"\u003eImmunologic effects:\u003c\/strong\u003e Any agent intended to “normalize” immunity could theoretically produce \u003cstrong data-start=\"6201\" data-end=\"6228\"\u003eundesired immune shifts\u003c\/strong\u003e in susceptible individuals; without robust pharmacovigilance-grade datasets, true incidence is unknown.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"6334\" data-end=\"6337\"\u003e\n\u003ch2 data-start=\"6339\" data-end=\"6365\"\u003e7) Regulatory landscape\u003c\/h2\u003e\n\u003cp data-start=\"6366\" data-end=\"6595\"\u003eCrystagen is typically marketed as a \u003cstrong data-start=\"6403\" data-end=\"6465\"\u003ebiologically active food supplement \/ peptide bioregulator\u003c\/strong\u003e rather than an FDA\/EMA-approved therapeutic with standardized indications and labeling. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-start=\"6597\" data-end=\"6600\"\u003e\n\u003ch2 data-start=\"6602\" data-end=\"6672\"\u003e8) Future directions (what would make the science “clinical-grade”)\u003c\/h2\u003e\n\u003cp data-start=\"6673\" data-end=\"6768\"\u003eIf Crystagen were to be advanced to modern therapeutic standards, the high-value work would be:\u003c\/p\u003e\n\u003col data-start=\"6770\" data-end=\"7365\"\u003e\n\u003cli data-start=\"6770\" data-end=\"6963\"\u003e\n\u003cp data-start=\"6773\" data-end=\"6963\"\u003e\u003cstrong data-start=\"6773\" data-end=\"6814\"\u003eDefinitive identity \u0026amp; standardization\u003c\/strong\u003e\u003cbr data-start=\"6814\" data-end=\"6817\"\u003eClarify whether the active is AC-6 (thymus peptide complex), a specific short peptide, or a mixture; publish \u003cstrong data-start=\"6929\" data-end=\"6940\"\u003eMS\/HPLC\u003c\/strong\u003e and impurity profiles.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6965\" data-end=\"7094\"\u003e\n\u003cp data-start=\"6968\" data-end=\"7094\"\u003e\u003cstrong data-start=\"6968\" data-end=\"6992\"\u003eHuman PK\/PD bridging\u003c\/strong\u003e\u003cbr data-start=\"6992\" data-end=\"6995\"\u003eDemonstrate measurable exposure (or mucosal engagement) and immune target engagement biomarkers.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7096\" data-end=\"7365\"\u003e\n\u003cp data-start=\"7099\" data-end=\"7365\"\u003e\u003cstrong data-start=\"7099\" data-end=\"7129\"\u003eControlled clinical trials\u003c\/strong\u003e\u003cbr data-start=\"7129\" data-end=\"7132\"\u003eDefine population (post-infectious immune dysfunction, older adults with immunosenescence markers, etc.), prespecify endpoints (B-cell\/T-cell phenotyping, vaccine response, infection incidence), and run blinded randomized studies.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003chr data-start=\"7367\" data-end=\"7370\"\u003e\n\u003ch2 data-start=\"7372\" data-end=\"7414\"\u003eSelected references (most load-bearing)\u003c\/h2\u003e\n\u003cul data-start=\"7415\" data-end=\"8026\"\u003e\n\u003cli data-start=\"7415\" data-end=\"7560\"\u003e\n\u003cp data-start=\"7417\" data-end=\"7560\"\u003eOrganotypic spleen model showing Crystagen’s B-cell marker effects and limited renewal-marker impact: \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7561\" data-end=\"7728\"\u003e\n\u003cp data-start=\"7563\" data-end=\"7728\"\u003eBrochure positioning Crystagen for immune normalization after infections\/stress\/aging and showing labeling inconsistencies: \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7729\" data-end=\"7909\"\u003e\n\u003cp data-start=\"7731\" data-end=\"7909\"\u003eThymalin review mentioning athlete immune normalization signals with oral Crystagen + other peptides (HSPA1A\/IL-6; infection incidence): \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7910\" data-end=\"8026\"\u003e\n\u003cp data-start=\"7912\" data-end=\"8026\"\u003eExample product listing identifying Crystagen as AC-6 (thymus peptides)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":52684841648466,"sku":null,"price":55.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/Crystagen_20mg.png?v=1770834797","url":"https:\/\/sciencepeptideslab.com\/products\/crystagen-20mg-vial","provider":"Science Peptides Lab","version":"1.0","type":"link"}